CYLD Antibody

CYLD is a 956 aa, cytoplasmic, deubiquitinating enzyme belonging to the ubiquitin carboxy-terminal hydrolases (UCH) family of proteins with three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains, a proline rich region, a SH3 binding domain and a sequence homology to catalytic domain of UCH. CYLD is identified as a tumor suppressor protein affecting the JNK signaling pathway. CYLD is a negative regulator of TRAF2 and NF-kappa-B signaling pathway and is also known to have receptor-dependent role in regulating the I-kappa-B kinase pathway. It also has a deubiquitinating activity that is directed towards non-Lys-48-linked polyubiquitin chains and TRAP1 is a novel substrate for deubiquitination. Mutated CYLD is known to be associated with cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 1 application: WB.

Showing Publication 1 - 1 of 1.

Publication using NB100-56461	Applications	Species
Moranta D, V Regueiro, C March et al. Klebsiella pneumoniae capsule polysaccharide impedes the expression of beta-defensins by airway epithelial cells. Infect & Immun 2010-01-01 [PMID: 20008534] (WB, Human) Details: CYLD (IMG-5815A) WB, Fig 6C, Fig 7A, Fig 7B, A549 human lung carcinoma cells.	WB	Human

Array NB100-56461

• CYLD Antibodies
• CYLD ELISA Kits
• CYLD Lysates
• CYLD Proteins